Clinical Trial Update: A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of XIAP antisense AEG35156 with gemcitabine in advanced pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• AEG35156 (XIAP antisense oligonucleotide)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Aegera Therapeutics | Conditions: Carcinoma, Pancreas | Phase 1, Phase 2 | Status: TERMINATED